Chemoenzymatic syntheses of fluorine-18-labeled disaccharides from FDG yield potent sensors of living bacteria in vivo
Sorlin, A.; Lopez Alvarez, M.; Rabbitt, S.; Alanizi, A.; Shuere, B.; Bobba, K. N.; Blecha, J.; Sakhamuri, S.; Evans, M.; Bayles, K. J.; Flavell, R.; Rosenberg, O.; Sriram, R.; Desmet, T.; Nidetzky, B.; Engel, J.; Ohliger, M.; Fraser, J.; Wilson, D. M.
Show abstract
Chemoenzymatic techniques have been applied extensively to pharmaceutical development, most effectively when routine synthetic methods fail. The regioselective and stereoselective construction of structurally complex glycans is an elegant application of this approach, that is seldom applied to positron emission tomography (PET) tracers. We sought a method to dimerize 2-deoxy-[18F]-fluoro-D-glucose ([18F]FDG), the most common tracer used in clinical imaging, to form [18F]-labeled disaccharides for detecting microorganisms in vivo based on their bacteria-specific glycan incorporation. When [18F]FDG was reacted with {beta}-D-glucose-1-phosphate in the presence of maltose phosphorylase, both the -1,4 and -1,3-linked products 2-deoxy-[18F]-fluoro-maltose ([18F]FDM) and 2-deoxy-2-[18F]-fluoro-sakebiose ([18F]FSK) were obtained. This method was further extended with the use of trehalose (,-1,1), laminaribiose ({beta}-1,3), and cellobiose ({beta}-1,4) phosphorylases to synthesize 2-deoxy-2-[18F]fluoro-trehalose ([18F]FDT), 2-deoxy-2-[18F]fluoro-laminaribiose ([18F]FDL), and 2-deoxy-2-[18F]fluoro-cellobiose ([18F]FDC). We subsequently tested [18F]FDM and [18F]FSK in vitro, showing accumulation by several clinically relevant pathogens including Staphylococcus aureus and Acinetobacter baumannii, and demonstrated their specific uptake in vivo. The lead sakebiose-derived tracer [18F]FSK was stable in human serum and showed high uptake in preclinical models of myositis and vertebral discitis-osteomyelitis. Both the synthetic ease, and high sensitivity of [18F]FSK to S. aureus including methicillin-resistant (MRSA) strains strongly justify clinical translation of this tracer to infected patients. Furthermore, this work suggests that chemoenzymatic radiosyntheses of complex [18F]FDG-derived oligomers will afford a wide array of PET radiotracers for infectious and oncologic applications.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1 90%
- Intravital Deep-Tumor Single-Beam 2-, 3- and 4-Photon Microscopy 90%
- Revealing intact neuronal circuitry in centimeter-sized formalin-fixed paraffin-embedded brain 90%
Similar papers in this journal
- Whole-body PET imaging of SIV using anti-Env probes fails to reveal regions of specific uptake in rhesus macaques 94%
- Development of radiofluorinated MLN-4760 derivatives for PET imaging of the SARS-CoV-2 entry receptor ACE2 93%
- Preclinical evaluation of the novel CHDI-650 PET ligand for non-invasive quantification of mutant huntingtin aggregates in Huntington's disease 93%
Similar papers in this journal
- Synthetically mannosylated antigens induce antigen-specific humoral tolerance and reduce anti-drug antibody responses to immunogenic biologics 89%
- An Omic and Multidimensional Spatial Atlas from Serial Biopsies of an Evolving Metastatic Breast Cancer 89%
- Hypoxia-Sensing CAR T-Cells Provide Safety and Efficacy in Treating Solid Tumors 89%
Similar papers in this journal
- Radiosynthesis and Preclinical Evaluation of Ga-NOTA-Folate for PET Imaging of Folate Receptor βPositive Macrophages 95%
- 68Ga-Bisphosphonates for the Imaging of Extraosseous Calcification by Positron Emission Tomography 93%
- -Labeled PARP-1 PET Imaging of PSMA Targeted Alpha Particle Radiotherapy Response 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.